{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:57Z","timestamp":1792788717602,"version":"4.5.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling (n = 88), CIBERSORT, and multiplex immunohistochemistry (n = 131) to characterize the immunoprofile of cHL TME and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and -noninflamed TME. Several macrophage-related genes were upregulated in samples with the non\u2013T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages. A cluster with high proportions of checkpoint protein (programmed cell death protein 1, PD-1 ligands, indoleamine 2,3 dioxygenase 1, lymphocyte-activation gene 3, and T-cell immunoglobulin and mucin domain containing protein 3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs 96%; P = .010) and remained an independent prognostic factor for OS in multivariable analysis (HR, 4.34; 95% CI, 1.05-17.91; P = .043). cHL samples with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples (P &amp;lt; .001) and in an expansion cohort of 84 cHL relapse samples (P = .048). Our findings demonstrate the impact of T cell- and macrophage-mediated checkpoint system on the survival of patients with cHL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006189","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:02:34Z","timestamp":1640296954000},"page":"1919-1931","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-8624","authenticated-orcid":false,"given":"Kristiina","family":"Karihtala","sequence":"first","affiliation":[{"name":"Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"},{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-0757","authenticated-orcid":false,"given":"Suvi-Katri","family":"Leivonen","sequence":"additional","affiliation":[{"name":"Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"},{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Helsinki University Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong Chun","family":"Chan","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-7373","authenticated-orcid":false,"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[{"name":"Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland;"},{"name":"Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland;"},{"name":"iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"1","key":"2022032115290125400_B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"2022032115290125400_B2","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/ijms20102416","article-title":"Formation of the immunosuppressive microenvironment of classic Hodgkin lymphoma and therapeutic approaches to counter it","volume":"20","author":"Aldinucci","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"1","key":"2022032115290125400_B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The role of T cells in the microenvironment of Hodgkin lymphoma","volume":"99","author":"Wein","year":"2016","journal-title":"J Leukoc Biol."},{"issue":"6","key":"2022032115290125400_B4","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3324\/haematol.2019.243287","article-title":"Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP","volume":"106","author":"Jachimowicz","year":"2021","journal-title":"Haematologica."},{"issue":"12","key":"2022032115290125400_B5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical Hodgkin lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"5","key":"2022032115290125400_B6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood."},{"issue":"26","key":"2022032115290125400_B7","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1200\/JCO.2005.55.013","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma","volume":"23","author":"Re","year":"2005","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022032115290125400_B8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","article-title":"Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells","volume":"11","author":"Alvaro","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2022032115290125400_B9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAI.0b013e3181c7138b","article-title":"The role of cytotoxic and regulatory T cells in relapsed\/refractory Hodgkin lymphoma","volume":"18","author":"Koreishi","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"1","key":"2022032115290125400_B10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.12987","article-title":"An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome","volume":"100","author":"Hollander","year":"2018","journal-title":"Eur J Haematol."},{"issue":"2","key":"2022032115290125400_B11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","article-title":"Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome","volume":"31","author":"Greaves","year":"2013","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022032115290125400_B12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol Oncol."},{"issue":"7","key":"2022032115290125400_B13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica."},{"issue":"1","key":"2022032115290125400_B14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell."},{"issue":"10","key":"2022032115290125400_B15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med."},{"issue":"2","key":"2022032115290125400_B16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2010.031542","article-title":"Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma","volume":"96","author":"Kamper","year":"2011","journal-title":"Haematologica."},{"issue":"3","key":"2022032115290125400_B17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/annonc\/mdr157","article-title":"Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin\u2019s lymphoma","volume":"23","author":"Azambuja","year":"2012","journal-title":"Ann Oncol."},{"issue":"5","key":"2022032115290125400_B18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3109\/10428194.2013.824079","article-title":"CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma","volume":"55","author":"Kayal","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022032115290125400_B19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","article-title":"Checkpoint inhibitors in hematological malignancies","volume":"10","author":"Ok","year":"2017","journal-title":"J Hematol Oncol."},{"issue":"23","key":"2022032115290125400_B20","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022032115290125400_B21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022032115290125400_B22","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv."},{"issue":"4","key":"2022032115290125400_B23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers12040877","article-title":"Prognostic impact of tumor-associated macrophages on survival is checkpoint dependent in classical Hodgkin lymphoma","volume":"12","author":"Karihtala","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"3","key":"2022032115290125400_B24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"2022032115290125400_B25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3324\/haematol.2018.200105","article-title":"T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma","volume":"104","author":"Leivonen","year":"2019","journal-title":"Haematologica."},{"issue":"6","key":"2022032115290125400_B26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J Clin Oncol."},{"issue":"32","key":"2022032115290125400_B27","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022032115290125400_B28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods."},{"issue":"10","key":"2022032115290125400_B29","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"issue":"1","key":"2022032115290125400_B30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat Protoc."},{"issue":"11","key":"2022032115290125400_B31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"2022032115290125400_B32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.intimp.2017.03.024","article-title":"IDO1: an important immunotherapy target in cancer treatment","volume":"47","author":"Li","year":"2017","journal-title":"Int Immunopharmacol."},{"issue":"10","key":"2022032115290125400_B33","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/cancers11101484","article-title":"Migration properties distinguish tumor cells of classical Hodgkin lymphoma from anaplastic large cell lymphoma cells","volume":"11","author":"Goncharova","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2022032115290125400_B34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12079-018-0486-y","article-title":"Comprehensive network map of interferon gamma signaling","volume":"12","author":"Bhat","year":"2018","journal-title":"J Cell Commun Signal."},{"issue":"9","key":"2022032115290125400_B35","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-10-3327","article-title":"The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma","volume":"17","author":"Hohaus","year":"2011","journal-title":"Clin Cancer Res."},{"key":"2022032115290125400_B36","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1038\/bcj.2017.102","article-title":"Erratum: The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor","volume":"8","author":"Wu","year":"2018","journal-title":"Blood Cancer J."},{"issue":"17","key":"2022032115290125400_B37","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"key":"2022032115290125400_B38","first-page":"257","article-title":"Expression of the immune checkpoint regulators LAG-3 and Tim-3 in classical Hodgkin lymphoma","volume":"4","author":"El Halabi","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2022032115290125400_B39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2407-14-335","article-title":"Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study","volume":"14","author":"Choe","year":"2014","journal-title":"BMC Cancer."},{"issue":"22","key":"2022032115290125400_B40","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022032115290125400_B41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2020.08.019","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell."},{"issue":"25","key":"2022032115290125400_B42","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood."},{"issue":"8","key":"2022032115290125400_B43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood."},{"key":"2022032115290125400_B44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"2022032115290125400_B45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"9","key":"2022032115290125400_B46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"31","key":"2022032115290125400_B47","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022032115290125400_B48","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022032115290125400_B49","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"10","key":"2022032115290125400_B50","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022008775","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1919\/1881764\/advancesadv2021006189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1919\/1881764\/advancesadv2021006189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:29:54Z","timestamp":1647876594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/6\/1919\/483245\/Checkpoint-protein-expression-in-the-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006189","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022008775","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}